165 related articles for article (PubMed ID: 24024897)
1. RRM1 and RRM2 pharmacogenetics: association with phenotypes in HapMap cell lines and acute myeloid leukemia patients.
Cao X; Mitra AK; Pounds S; Crews KR; Gandhi V; Plunkett W; Dolan ME; Hartford C; Raimondi S; Campana D; Downing J; Rubnitz JE; Ribeiro RC; Lamba JK
Pharmacogenomics; 2013 Sep; 14(12):1449-66. PubMed ID: 24024897
[TBL] [Abstract][Full Text] [Related]
2. Genetic variants in cytosolic 5'-nucleotidase II are associated with its expression and cytarabine sensitivity in HapMap cell lines and in patients with acute myeloid leukemia.
Mitra AK; Crews KR; Pounds S; Cao X; Feldberg T; Ghodke Y; Gandhi V; Plunkett W; Dolan ME; Hartford C; Raimondi S; Campana D; Downing J; Rubnitz JE; Ribeiro RC; Lamba JK
J Pharmacol Exp Ther; 2011 Oct; 339(1):9-23. PubMed ID: 21712425
[TBL] [Abstract][Full Text] [Related]
3. Pharmacogenetics of deoxycytidine kinase: identification and characterization of novel genetic variants.
Lamba JK; Crews K; Pounds S; Schuetz EG; Gresham J; Gandhi V; Plunkett W; Rubnitz J; Ribeiro R
J Pharmacol Exp Ther; 2007 Dec; 323(3):935-45. PubMed ID: 17855478
[TBL] [Abstract][Full Text] [Related]
4. Association of genetic polymorphisms in genes involved in Ara-C and dNTP metabolism pathway with chemosensitivity and prognosis of adult acute myeloid leukemia (AML).
Zhu KW; Chen P; Zhang DY; Yan H; Liu H; Cen LN; Liu YL; Cao S; Zhou G; Zeng H; Chen SP; Zhao XL; Chen XP
J Transl Med; 2018 Apr; 16(1):90. PubMed ID: 29631596
[TBL] [Abstract][Full Text] [Related]
5. RNA expression of genes involved in cytarabine metabolism and transport predicts cytarabine response in acute myeloid leukemia.
Abraham A; Varatharajan S; Karathedath S; Philip C; Lakshmi KM; Jayavelu AK; Mohanan E; Janet NB; Srivastava VM; Shaji RV; Zhang W; Abraham A; Viswabandya A; George B; Chandy M; Srivastava A; Mathews V; Balasubramanian P
Pharmacogenomics; 2015 Jul; 16(8):877-90. PubMed ID: 26083014
[TBL] [Abstract][Full Text] [Related]
6. P53 suppresses ribonucleotide reductase via inhibiting mTORC1.
He Z; Hu X; Liu W; Dorrance A; Garzon R; Houghton PJ; Shen C
Oncotarget; 2017 Jun; 8(25):41422-41431. PubMed ID: 28507282
[TBL] [Abstract][Full Text] [Related]
7. RRM1, RRM2 and ERCC2 Gene Polymorphisms in Coronary Artery Disease.
Altinkilic EM; Isbir S; Gormus U; Yilmaz SG; Dalan AB; Duman S; Isbir T
In Vivo; 2016 09-10; 30(5):611-5. PubMed ID: 27566080
[TBL] [Abstract][Full Text] [Related]
8. Excision repair cross-complementing gene-1, ribonucleotide reductase subunit M1, ribonucleotide reductase subunit M2, and human equilibrative nucleoside transporter-1 expression and prognostic value in biliary tract malignancy.
Fisher SB; Fisher KE; Patel SH; Lim MG; Kooby DA; El-Rayes BF; Staley CA; Adsay NV; Farris AB; Maithel SK
Cancer; 2013 Jan; 119(2):454-62. PubMed ID: 22760605
[TBL] [Abstract][Full Text] [Related]
9. Prognostic and Immunological Potential of Ribonucleotide Reductase Subunits in Liver Cancer.
Yin X; Jiang K; Zhou Z; Yu H; Yan D; He X; Yan S
Oxid Med Cell Longev; 2023; 2023():3878796. PubMed ID: 36713030
[TBL] [Abstract][Full Text] [Related]
10. Genetic factors influencing cytarabine therapy.
Lamba JK
Pharmacogenomics; 2009 Oct; 10(10):1657-74. PubMed ID: 19842938
[TBL] [Abstract][Full Text] [Related]
11. RNA-dependent inhibition of ribonucleotide reductase is a major pathway for 5-azacytidine activity in acute myeloid leukemia.
Aimiuwu J; Wang H; Chen P; Xie Z; Wang J; Liu S; Klisovic R; Mims A; Blum W; Marcucci G; Chan KK
Blood; 2012 May; 119(22):5229-38. PubMed ID: 22517893
[TBL] [Abstract][Full Text] [Related]
12. Polymorphisms at microRNA binding sites of Ara-C and anthracyclines-metabolic pathway genes are associated with outcome of acute myeloid leukemia patients.
Cao HX; Miao CF; Yan L; Tang P; Zhang LR; Sun L
J Transl Med; 2017 Nov; 15(1):235. PubMed ID: 29141648
[TBL] [Abstract][Full Text] [Related]
13. Investigation of some DNA repair genes association in non small cell lung cancer.
Coskunpinar E; Yildiz P; Aynaci E; Turna A; Musteri Oltulu Y; Hekimoglu E; Isbir T; Yaylim I
Cell Mol Biol (Noisy-le-grand); 2015 Dec; 61(8):57-62. PubMed ID: 26718430
[TBL] [Abstract][Full Text] [Related]
14. Implication of checkpoint kinase-dependent up-regulation of ribonucleotide reductase R2 in DNA damage response.
Zhang YW; Jones TL; Martin SE; Caplen NJ; Pommier Y
J Biol Chem; 2009 Jul; 284(27):18085-95. PubMed ID: 19416980
[TBL] [Abstract][Full Text] [Related]
15. RRM1 *151A>T, RRM1 -756T>C, and RRM1 -585T>Gis associated with increased susceptibility of lung cancer in Chinese patients.
Xu XL; Zheng J; Mao WM; Ling ZQ
Cancer Med; 2016 Aug; 5(8):2084-90. PubMed ID: 27335251
[TBL] [Abstract][Full Text] [Related]
16. A Single Conserved Residue Mediates Binding of the Ribonucleotide Reductase Catalytic Subunit RRM1 to RRM2 and Is Essential for Mouse Development.
Specks J; Lecona E; Lopez-Contreras AJ; Fernandez-Capetillo O
Mol Cell Biol; 2015 Sep; 35(17):2910-7. PubMed ID: 26077802
[TBL] [Abstract][Full Text] [Related]
17. A multicenter, open, non-comparative, phase II study of the combination of cladribine (2-chlorodeoxyadenosine), cytarabine, and G-CSF as induction therapy in refractory acute myeloid leukemia - a report of the Polish Adult Leukemia Group (PALG).
Wrzesień-Kuś A; Robak T; Lech-Marańda E; Wierzbowska A; Dmoszyńska A; Kowal M; Hołowiecki J; Kyrcz-Krzemień S; Grosicki S; Maj S; Hellmann A; Skotnicki A; Jedrzejczak W; Kuliczkowski K;
Eur J Haematol; 2003 Sep; 71(3):155-62. PubMed ID: 12930315
[TBL] [Abstract][Full Text] [Related]
18. An analysis of human equilibrative nucleoside transporter-1, ribonucleoside reductase subunit M1, ribonucleoside reductase subunit M2, and excision repair cross-complementing gene-1 expression in patients with resected pancreas adenocarcinoma: implications for adjuvant treatment.
Fisher SB; Patel SH; Bagci P; Kooby DA; El-Rayes BF; Staley CA; Adsay NV; Maithel SK
Cancer; 2013 Jan; 119(2):445-53. PubMed ID: 22569992
[TBL] [Abstract][Full Text] [Related]
19. Identification of genetic variants and gene expression relationships associated with pharmacogenes in humans.
Huang RS; Duan S; Kistner EO; Zhang W; Bleibel WK; Cox NJ; Dolan ME
Pharmacogenet Genomics; 2008 Jun; 18(6):545-9. PubMed ID: 18496134
[TBL] [Abstract][Full Text] [Related]
20. The translational repressor 4E-BP1 regulates RRM2 levels and functions as a tumor suppressor in Ewing sarcoma tumors.
Goss KL; Koppenhafer SL; Waters T; Terry WW; Wen KK; Wu M; Ostergaard J; Gordon PM; Gordon DJ
Oncogene; 2021 Jan; 40(3):564-577. PubMed ID: 33191406
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
